Vyome Holdings (HIND) Convertible Debt (2024)
Vyome Holdings (HIND) posted quarterly Convertible Debt of $3.6 million for Q4 2024, up 2.91% quarter-over-quarter from $3.5 million in Q3 2024.
Vyome Holdings (HIND) Convertible Debt (2024) Analysis & Trends
Vyome Holdings' Convertible Debt history runs 1 years deep, the most recent figure standing at $3.6 million for Q4 2024.
- In Q4 2024, Convertible Debt changed N/A year-over-year to $3.6 million; the TTM figure through Dec 2024 stood at $3.6 million (changed N/A YoY), while the FY2024 annual figure was $3.6 million, changed N/A from the prior year.
- Convertible Debt for Q4 2024 stood at $3.6 million, up from $3.5 million in the prior quarter.
- The five-year high for Convertible Debt was $3.6 million in Q4 2024, with the low at $3.5 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.99 Bn | 132.14 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.80 Bn | 78.80 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.38 Bn | 60.19 Bn | 1.37 Bn |
| 4 | Moderna | 60.70 Bn | 55.56 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.06 Bn | 668.28 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.21 Bn | 26.37 Bn | - |
| 10 | Vyome Holdings | 16.00 Mn | 8.11 Mn | 11,658.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 3.59 Mn |
| Sep 30, 2024 | 3.49 Mn |